Literature DB >> 2899601

Expression of the J11d marker on peripheral T lymphocytes of MRL-lpr/lpr mice.

A Seth1, R H Pyle, M Nagarkatti, P S Nagarkatti.   

Abstract

MRL-lpr/lpr (lpr) mice spontaneously develop massive lymphadenopathy resulting from the expansion of a unique population of Thy-1+ cells which are CD4- and CD8- (double negative) and the nature of which is not clear. The antibody J11d has been shown to define a differentiation Ag found on immature thymocytes but not on mature and functional peripheral CD4+ or CD8+ T cells. To analyze the possible relationship between the lpr double-negative T cells and the thymocytes, we investigated the simultaneous expression of J11d and Thy 1 Ag on the double-negative lpr lymph node cells by using two-color immunofluorescent staining technique. We observed that lpr mice at 3 to 4 weeks of age, before the onset of lymphadenopathy, did not have significant numbers (less than 4%) of J11d+ T cells in the periphery, similar to the number found in the control MRL +/+ mice. However, with increasing age of approximately 8 to 10 weeks and coinciding with the appearance of lymphadenopathy, a significant number (approximately 35%) of J11d+ Thy-1+ cells started appearing in the periphery of lpr mice and was maintained until the mice died at 20 to 24 weeks of age. The J11d+ T cells belonged to the abnormal double-negative T cell pool, inasmuch as J11d+ CD4+ or J11d+ CD8+ cells were absent in the lymph nodes of 20-wk-old lpr mice. Furthermore, 20-wk-old lpr mice demonstrated increased numbers (approximately 41%) of double-negative T cells in the thymus, a significant proportion of which were J11d+. In contrast, the 20-wk-old +/+ mice or 4-wk-old lpr mice had only 4% double-negative T cells in the thymus. The present study suggests that a significant number of peripheral double-negative T cells of lpr mice bear the immature thymic differentiation Ag J11d. The possibility that the accumulation of double-negative T cells results from abnormal peripheralization of double-negative J11d+ thymocytes, before complete differentiation into CD4+ or CD8+ T cells, is discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899601

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Aldicarb suppresses macrophage but not natural killer (NK) cell-mediated cytotoxicity of tumor cells.

Authors:  R S Selvan; T N Dean; H P Misra; P S Nagarkatti; M Nagarkatti
Journal:  Bull Environ Contam Toxicol       Date:  1989-11       Impact factor: 2.151

2.  Overexpression of src family gene for tyrosine-kinase p59fyn in CD4-CD8- T cells of mice with a lymphoproliferative disorder.

Authors:  T Katagiri; K Urakawa; Y Yamanashi; K Semba; T Takahashi; K Toyoshima; T Yamamoto; K Kano
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14.

Authors:  A Seth; L Gote; M Nagarkatti; P S Nagarkatti
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

4.  Different expression of T-cell receptor beta-chain variable region genes in lymph nodes of lpr mice with different alleles of the major histocompatibility complex.

Authors:  S Ohga; Y Yoshikai; K Kishihara; G Matsuzaki; M Ogimoto; K Nomoto
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

5.  Double-negative T cells from MRL-lpr/lpr mice mediate cytolytic activity when triggered through adhesion molecules and constitutively express perforin gene.

Authors:  D M Hammond; P S Nagarkatti; L R Goté; A Seth; M R Hassuneh; M Nagarkatti
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

6.  T cells with gamma/delta T cell receptors (TCR) of intestinal type are preferentially expanded in TCR-alpha-deficient lpr mice.

Authors:  D P Hughes; A Hayday; J E Craft; M J Owen; I N Crispe
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.